pharma.be lauds strong pharma sector, but warns of dark clouds

22 June 2026

This year, Belgian trade group pharma.be celebrates its 60thanniversary. Throughout all these decades, biopharmaceutical companies have contributed to cutting-edge scientific research through partnerships with universities and research institutions, it noted.

Clinical studies are initiated, placing Belgium among the leading countries in Europe in this field. For the many patients participating and for the hospitals, which, thanks to their involvement, have the first access to the latest breakthroughs, this is an undeniable advantage. But the sector has also built up an enormous footprint in terms of production and distribution, with many people working for the sector directly or indirectly.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Company Spotlight



More Features in Pharmaceutical